04 · 21 proprietary layers
Layer 14 of 21 · Clinical integration
Treatment Response Prediction Likelihood of response and resistance.
Why it's needed
What response-related evidence or estimates can be reviewed for a possible therapy?
What it draws on
4 of 8 evidence domains.
What it produces
A response-related assessment with a clear explanation of evidence and uncertainty.
Why it's essential
Layer 14 of 21.
1 · What it does
What Treatment Response Prediction does
When a therapy is being considered, it helps to see what is known about response in tumours with similar features. This layer is intended to organise response-related evidence and any supported estimates, and to make their limits explicit.
2 · Scientific question
The question it addresses
What response-related evidence or estimates can be reviewed for a possible therapy?
Intended function
Describe the supported response-related method and the evidence that underpins it.
3 · Data inputs and required context
What it draws on
- 01 Molecular & genomic
- 05 Immune landscape
- 06 Treatment exposure
- 08 Evidence ecosystem
Molecular and immune findings, treatment history and the relevant evidence base.
4 · Scientific basis
The science behind it
Scientific basis
Response-related estimates range from evidence summaries, such as published response rates in biomarker-defined groups, to statistical or machine-learning models. Individual-level prediction requires validation in comparable patients before it can be relied on.
5 · Output and evidence sources
What it produces
Main output
A response-related assessment with a clear explanation of evidence and uncertainty.
Output type
- Evidence-linked interpretation. Connects a finding to published or curated evidence, which has a source and a date.
- Computational inference. Estimated by analysis of available data rather than measured directly.
6 · Why it\u2019s essential
How it powers the Twin
Adds response-related context to options identified by AccessMatch, read with ResistMap and ToxCast.
Report section
Capability
ExploreReview treatment-relevant evidence, resistance-related findings and potential trial matches.
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Clinicians
Response-related evidence for options under consideration, with validation status labelled.
Doctor & Clinical TeamPatients & caregivers
No analysis can promise how a person will respond to a treatment.
Patient & Caregiver8 · Dependencies and limitations
Limitations
- Promises of individual response must be avoided.
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Population-level evidence is presented as such; any model-based estimate carries its validation status and confidence.
10 · Claim boundary
What this layer does not establish
It does not establish whether this patient will respond to a particular treatment.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process